Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 24, 2008

View Archived Issues

Bendamustine-rituximab combination active in relapsed mantle cell and indolent B-cell lymphoma

Phase II study assesses dose titration, depression with intranasal antiobesity drug PYY-3-36

Novartis: Q3 review

Activity seen with OSI-930 in phase I study in solid tumor patients

Further Empatic clinical data show improved quality of life, early responses

Nefopam acts against shivering in healthy volunteers

Recent Tufts College and TransTech patents disclose novel antidiabetic agents

Recent Xenon, Merck Frosst and GSK patents impart novel analgesic agents

Novexel reports positive phase II NXL-103 results in adults with CAP

Newron reports positive safety and tolerability results for HF-0220 in AD

DUSA reports results for phase IIb Levulan PDT trial in acne

Schering-Plough updates recent pipeline and business developments

NMS and Genentech sign collaboration agreement for antibody drug conjugates in cancer

New drug delivery agents reported in recent Emisphere Technologies patent

FDA maintains clinical holds on two IND applications for Dynavax and Merck & Co.'s Heplisav

ViroPharma completes acquisiton of Lev Pharmaceuticals

Vernalis regains rights to portfolio of antiinflammatory compounds including V-85546

Glycotex initiates enrollment in phase IIb study of GLYC-101 in wound healing

ALK reports positive results from first follow-up year in GT-08 clinical study of Grazax

Vitae reacquires full rights to renin inhibitor program for hypertension from GSK

CytoDyn files new IND for proof-of-principle study to reconfirm dose range of Cytolin

Addrenex initiates phase II ADX-415 trial in hypertension

Medivir submits MAA to European regulatory authorities for Lipsovir

Opexa provides additional data for Tovaxin in multiple sclerosis

EMEA recommends temporary suspension of Acomplia marketing authorization in obese patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Neutrophils put the brakes on fat loss
BioWorld Science
Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained metabolic stress demands mechanisms that...